In:
Cancer Science, Wiley, Vol. 105, No. 3 ( 2014-03), p. 354-358
Abstract:
We planed a phase I study of sorafenib combined with transcatheter arterial infusion (TAI) of cisplatin for advanced hepatocellular carcinoma. The combination of sorafenib at 800 mg/day with TAI of cisplatin at 65 mg/m 2 /cycle was determined to be the recommended regimen.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2014.105.issue-3
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6